EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EVALUATION OF BIOFILM PRODUCTION IN STAPHYLOCOCCUS AUREUS FROM CYSTIC FIBROSIS PATIENTS

Gordana Mirchevska, Nadica Krsteva, Sara Nedelkoska Kokaroska, Radomir Jovchevski, Elizabeta Janchevska, Aleksandra Kacarska, Valentina Cvejoska Cholakovska, Stojka Fushtikj Naceva, Vesna Kotevska

Academic Medical Journal · 18.06.2026 · 6 (2) · 10-18

DOI: 10.53582/07p86p95 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Academic Medical Journal, online erschienen am 18.06.2026. Verfasst von Gordana Mirchevska und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) is a multisystemic, life-limiting autosomal recessive disease. It is characterized by impaired chloride transport, which results in mucus retention that predisposes patients to chronic respiratory infections. Among the most common pathogens isolated from CF patients is Staphylococcus aureus, which possesses the ability to form biofilms. This ability is a key factor contributing to antimicrobial resistance and persistence. This study aimed to evaluate biofilm production in 41 clinical isolates of S. aureus from CF patients and 11 non-CF controls, using the quantitative colorimetric microtiter plate assay. Results showed that 51% (21/41) of CF isolates were methicillin-sensitive S. aureus (MSSA), while 49% (20/41) were methicillin-resistant S. aureus (MRSA). Among non-CF isolates, 27.3% (3/11) were MRSA and 72.7% (8/11) were MSSA. Biofilm production was observed in 32% (13/41) of CF S. aureus isolates. Among these, 46% (6/13) were MSSA and 54% (7/13) were MRSA. The biofilm phenotypes of CF isolates were distributed as follows: 6.8% strong, 24.4% moderate, and 68.3% weak or non-producers. In non-CF isolates, 18.2% (2/11) were biofilm producers, with one strong and one moderate producer; the remaining 82% (9/11) were weak or non-producers. These findings highlight the clinical relevance of biofilm production in CF-associated S. aureus infections and underscore the need for tailored antimicrobial strategies.

Zitieren

APA

Mirchevska, G., Krsteva, N., Kokaroska, S. N., Jovchevski, R., Janchevska, E., Kacarska, A., Cholakovska, V. C., Naceva, S. F., & Kotevska, V. (2026). EVALUATION OF BIOFILM PRODUCTION IN STAPHYLOCOCCUS AUREUS FROM CYSTIC FIBROSIS PATIENTS. Academic Medical Journal, 6(2), 10-18. https://doi.org/10.53582/07p86p95

Vancouver

Mirchevska G, Krsteva N, Kokaroska SN, Jovchevski R, Janchevska E, Kacarska A, et al. EVALUATION OF BIOFILM PRODUCTION IN STAPHYLOCOCCUS AUREUS FROM CYSTIC FIBROSIS PATIENTS. Academic Medical Journal. 2026;6(2):10-18. doi:10.53582/07p86p95

BibTeX
@article{Mirchevska2026,
  author = {Mirchevska, Gordana and Krsteva, Nadica and Kokaroska, Sara Nedelkoska and Jovchevski, Radomir and Janchevska, Elizabeta and Kacarska, Aleksandra and Cholakovska, Valentina Cvejoska and Naceva, Stojka Fushtikj and Kotevska, Vesna},
  title = {EVALUATION OF BIOFILM PRODUCTION IN STAPHYLOCOCCUS AUREUS FROM CYSTIC FIBROSIS PATIENTS},
  journal = {Academic Medical Journal},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {10--18},
  doi = {10.53582/07p86p95}
}
Kostenlos starten →